OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
COVID-19 and investments will shape the outsourcing industry for the near term.
Advances in technology are accelerating the development and manufacture of subunit vaccines.
December 03, 2021
Moderna’s agreement with the UK government includes 29 million COVID-19 vaccine doses for delivery in 2022 and 31 million doses for delivery in 2023.
December 02, 2021
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers that should continue in the future.
The need for medicines to combat COVID-19 has impacted the way regulatory agencies carry out their operations.
November 29, 2021
Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.
The companies are testing their existing vaccines against the new variant of concern and are pursuing variant-specific versions.
The Comirnaty vaccine received a positive opinion from the EMA’s CHMP for children five to under 12 years of age.
Samsung Biologics will manufacture GreenLight BioSciences' COVID-19 vaccine candidate for clinical trials and commercial sales.
November 23, 2021
United States government contracts total approximately $1 billion to purchase sotrovimab, an investigational mAb.
November 19, 2021
FDA has amended its EUA for Pfizer-BioNTech’s and Moderna’s COVID-19 booster to include all individuals aged 18 or older.
EC has granted marketing authorization for Celltrion's Regkirona (regdanvimab, CT-P59) as a treatment for adults with COVID-19.